AELIS FARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.9 EUR | +0.78% |
|
-2.27% | -1.53% |
| Sales 2024 * | 54.03M 57.83M | Sales 2025 * | 12.4M 13.27M | Capitalization | 170M 182M |
|---|---|---|---|---|---|
| Net income 2024 * | 33M 35.32M | Net income 2025 * | -5M -5.35M | EV / Sales 2024 * | 0.99 x |
| Net cash position 2024 * | 117M 125M | Net cash position 2025 * | 106M 113M | EV / Sales 2025 * | 5.19 x |
| P/E ratio 2024 * |
-7.09
x | P/E ratio 2025 * |
-5.97
x | Employees | 26 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.78% | ||
| 1 week | -2.27% | ||
| Current month | -2.27% | ||
| 1 month | -1.53% | ||
| 3 months | -3.37% | ||
| 6 months | -3.37% | ||
| Current year | -1.53% |
1 week
12.80
13.20
1 month
12.8013.30
Current year
12.8013.60
1 year
12.8014.00
3 years
8.5614.48
5 years
8.5614.48
10 years
8.5614.48
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 63 | 13-10-06 | |
| Director of Finance/CFO | - | - | |
Helle Mengel
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 19-12-31 | |
François Thomas
BRD | Director/Board Member | 66 | 21-12-31 |
| Director/Board Member | 64 | 21-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 12.9 | +0.78% | 712 |
| 24-06-13 | 12.8 | -1.54% | 161 |
| 24-06-12 | 13 | +0.78% | 10 |
| 24-06-11 | 12.9 | -0.77% | 1,840 |
| 24-06-10 | 13 | -1.52% | 310 |
Real-time Euronext Paris, June 14, 2024 at 08:35 am EDT
More quotes
Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS).
The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).
Sector
Pharmaceuticals
Calendar
2024-09-15
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.9
EUR
Average target price
20.67
EUR
Spread / Average Target
+60.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.53% | 182M | |
| +50.70% | 791B | |
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B |
- Stock Market
- Equities
- AELIS Stock
